Lyon, France, December 6, 2022 — EDAP TMS SA (NASDAQ: EDAP) (the “Company”) today announced the hiring of medical capital equipment finance industry veteran Ken Mobeck as Chief Financial Officer of its US-based EDAP Technomed Inc. subsidiary. During his extensive career, Mr. Mobeck has demonstrated significant leadership expertise in driving innovative business growth while establishing a track record of creating lasting shareholder value.
Marc Oczachowski, Chairman and Chief Executive Officer of EDAP TMS, said: Ken has been a great addition to Ryan Rhodes’ team and will be key to supporting the continued expansion of the US organization and driving the continued strong growth of our US business. “
Ryan Rhodes, Chief Executive Officer of EDAP Technomed Inc. Over his 25+ years, he has extensive experience in financial leadership and building strong relationships to deliver results in all areas of finance. His medical device and investor relations experience at leading organizations, including Accuray, along with his knowledge of capital equipment, will be invaluable as we move forward. “
“EDAP Technomed Inc. is at a critical juncture in our organization’s growth. We look forward to providing access to the Focal One robotics technology,” said Mobeck.
Prior to joining EDAP Technomed, he served as Vice President of Finance and Investor Relations at medical device manufacturer Accuray Incorporated (Nasdaq: ARAY). During his tenure with the organization, he was responsible for driving major initiatives to improve the company’s performance. Prior to joining Accuray, he was the vice president of finance at Lumentum (Nasdaq:LITE), a leader in optical networks, where he went from $900 million to over $1.6 billion in just three years. Helped raise $900 million in debt to grow the business. Prior to Lumentum, he spent more than 20 years at Silicon Valley’s most innovative companies, including Silicon Graphics, Hewlett Packard (NYSE: HPQ), KLA (Nasdaq: KLAC), and Intel Corporation (Nasdaq: INTC). I was in a heavy job. There he has been involved in large-scale growth, business transformation, mergers and acquisitions. Notably, he grew his revenue from his $1.3 billion to his $2.7 billion in seven years while working for KLA.
about EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and markets worldwide minimally invasive medical devices using ultrasound technology for a variety of medical conditions. EDAP TMS has introduced Focal One® in Europe and the US as the answer to all requirements for ideal prostate tissue ablation, combining the latest in imaging and therapeutic modalities with a complete range of robotic HIFU devices. did. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company to offer a complete solution from diagnosis to local treatment of prostate cancer. EDAP TMS also manufactures and markets other medical devices such as the Sonolith® i-move lithotripter and lasers for treating urinary calculi using extracorporeal shock wave lithotripsy (ESWL). For more company information, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements. Such statements are based on management’s current expectations and are subject to numerous risks and uncertainties, including matters that are not yet known to us or that we do not currently consider material. There is no guarantee that the expected events will occur or that the objectives set will be achieved. Out is actually achieved. Important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements include, among other things, the clinical status and market acceptance of our HIFU devices; of ongoing market potential, and length. Severity of recent COVID-19 outbreaks. This includes on-demand business-wide impacts on our devices and services. Factors that could cause such differences also include those described in our filings with the Securities and Exchange Commission, particularly in the sections titled “Cautionary Statement Regarding Forward-Looking Information” and “Risk Factors.” Including but not limited to: Company annual report on Form 20-F.
company contact
Brandin Comfort
Investor Relations/Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
investor contact
John Frances
Life Science Advisors, LLC
212-915-2568
jfraunces@lifesciaadvisors.com
